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Antibiotic-resistant bacteria ‘superbugs’ are an emerging threat to public health
due to the decrease in effective antibiotics as well as the slowed pace of
development of new antibiotics to replace those that become ineffective. The need
for new antimicrobial agents is a well-documented issue relating to world health.
Tremendous efforts have been given to developing compounds that not only show
high efficacy, but also those that are less susceptible to resistance development in
the bacteria. However, the development of newer, stronger antibiotics which can
overcome these acquired resistances is still a scientific challenge because a new
mode of antimicrobial action is likely required. To that end, amphiphilic, cationic
polymers have emerged as a promising candidate for further development as an
antimicrobial agent with decreased potential for resistance development. These
polymers are designed to mimic naturally occurring host-defense antimicrobial
peptides which act on bacterial cell walls or membranes. Antimicrobial-peptide
mimetic polymers display antibacterial activity against a broad spectrum of bacteria
including drug-resistant strains and are less susceptible to resistance development
in bacteria. These polymers also showed selective activity to bacteria over
mammalian cells. Antimicrobial polymers provide a new molecular framework
for chemical modification and adaptation to tune their biological functions. The
peptide-mimetic design of antimicrobial polymers will be versatile, generating a
new generation of antibiotics toward implementation of polymers in biomedical
applications. © 2012 Wiley Periodicals, Inc.
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INTRODUCTION
The need for new antimicrobial agents is a well-documented issue relating to world health.1–6
The past 20 years have seen a dramatic increase in
the development of antibiotic resistance harbored
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by relatively common pathogenic bacterial species.
These resistances can arise from both natural
evolution/selective pressure as well as from the
improper use and administration of antibiotics at the
clinical level. Regardless of the origin of the resistance,
these new ‘superbugs’ require the development of
newer, stronger antibiotics which can overcome these
acquired resistances. Through the development of
these new compounds, significant effort has been given
to developing compounds that not only show high
efficacy, but also those that are less susceptible to
resistance development in the bacteria they target.
Amphiphilic, cationic polymers have emerged as
a promising candidate for further development as
an antimicrobial agent with decreased potential
for resistance development.7–10 These polymers are
designed using naturally occurring host-defense
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peptides (HDPs) or antimicrobial peptides (AMPs)
as a ‘molecular inspiration’, building on the selectivity
of these peptides imparted from their cationic,
amphiphilic nature.11 However, polymers exhibit
significant advantages over the peptide antimicrobials
in that polymers can be cost-effectively produced in
much greater quantities, have greater compatibility
with drug-delivery methodology, and provide a
flexible framework for chemical modification and
adaptation.
The chemical and structural diversity avail-
able to polymer chemists allow for great vari-
ability in the construction of cationic, amphiphilic
molecules designed to function as antimicrobials.
This diversity yields a significant amount of requi-
site investigation into mechanism of action, efficacy
and selectivity profiles, resistance potential, as well
as structure–activity relationships. In general, the
cationic, amphiphilic polymers exhibit selectivity to
bacterial targets through favorable electrostatic inter-
actions between the polymer and the highly negatively
charged bacterial cell surface.11 This electrostatic
interaction allows for broad-spectrum activity as most
bacterial surfaces maintain anionic properties. Once
bound, many polymers can significantly disrupt the
bacterial membrane(s), presumably by inserting the
hydrophobic moieties into the bilayer core.12–14 While
these are likely mechanisms, mounting evidence shows
that simple membrane disruption may be only one
component of a more complex series of effects bring-
ing about bacterial cell death.15,16
BACKGROUND
Antimicrobial or antibiotic resistance is an emerg-
ing threat due to the inherent loss of efficacy of
clinically prescribed antibiotics but also due to the
slowed pace of development of new antibiotics to
replace those that become ineffective.1,2,5,6 The devel-
opment of resistant organisms were first detected in
hospital settings as nosocomial infections but have
since spread and are now routinely agents of commu-
nity acquired infections. Clinically isolated resistant
organisms include bacteria, viruses, fungi, and para-
sites. While resistance in any pathogenic organism is
problematic, the problem of bacterial resistance has
taken a primary focus of interest due to widely pub-
licized examples [methicillin-resistant Staphylococcus
aureus (MRSA), for example] as well as the numer-
ous different strains which have shown resistance
development in a clinical setting including Acineto-
bacter baumannii, Neisseria gonorrhoeae, Klebsiella
pneumoniae, MRSA, multidrug-resistant Mycobac-
terium tuberculosis (MDR-TB), Vancomycin-resistant
Enterococci (VRE), and Vancomycin-intermediate/
resistant Staphylococcus aureus (VISA/VRSA).2 The
rapid emergence of these strains coupled with the
wide variety of antimicrobial agents that resistance
has developed against dictates the need for new,
highly effective antimicrobials that act on novel targets
or critical bacterial components to which resistance
cannot be evolved.
Host-Defense Antimicrobial Peptides
Host-defense AMPs have been extensively studied as
new alternatives for antibiotics because of little or no
susceptibility to the current resistance mechanisms
of bacteria.15–22 AMPs are a class of peptides in
the innate immunity, which protect the body from
invasion of microbes by quick killing action. The
structural feature of AMPs includes a relatively small
molecular size (10–50 amino acids) and cationic
amphiphilicity exerted by cationic and hydrophobic
side chains.18 One of the classes is α-helical AMPs
including magainin and LL-37, and these AMPs form
helix upon binding to bacterial cell membranes, and
the cationic and hydrophobic side chains are localized
on different side of helix15 (Figure 1(a)). AMPs attack
bacterial cell membranes, which causes membrane
permeabilization, leakage of cellular components,
and breakdown of membrane potential, resulting
in cell death. This contrasts the mode of action of
conventional antibiotics, which are generally enzyme
and DNA replication inhibitors. The activity of AMPs
is selective to bacteria over mammalian cells. This
is because of preferential binding of cationic AMPs
to high net negative charge on bacterial surfaces
over mammalian cells (Figure 1(b)). Several molecular
mechanisms of membrane permeabilization by AMPs
have been proposed: the peptides accumulate on
the cell membranes and form discrete pores in
the membrane (toroidal and barrel-stave models)
or disrupt the membrane nonspecifically (carpet
model)15,19 (Figure 1(c)).
Although an in-depth discussion of antimicro-
bial mechanism of AMPs is beyond the scope of this
review, recent studies on natural HDPs provided new
insights into the mechanism of these membrane-active
antimicrobials. Wong and coworkers investigated the
role of lipids and topological changes in the membrane
permeabilization by peptides and peptidomimetics
using small-angle X-ray scattering (SAXS).23 Natu-
ral peptides selectively permeabilized model bacterial
membranes, while they do not destabilize model
eukaryotic membranes. The HDP defensin generated
a negative Gaussian (saddle-splay) curvature in model
bacterial membranes composed of lipids that intrinsi-
cally induce negative curvature, which is necessary for
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FIGURE 1 | α-Helical cationic antimicrobial peptide
(AMP) and antimicrobial mechanism. (a) α-helical
structure of magainin-2 (pdbID: 2MAG). Cationic
residues are colored blue while hydrophobic residues are
green. (b) Representation of the selectivity of AMPs to
bacteria over mammalian cells based on coulombic
attraction. Anioinc lipid head groups are shaded red,
zwitterionic lipid head groups gray, and the peptide
color scheme is the same as (a). (c) Proposed
membrane-permeabilization models. (Reprinted with
permission from Ref 15. Copyright 2005 Nature
Publication Group)
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pore formation. The ability of peptides to selectively
generate Gaussian curvature, or the Gaussian curva-
ture selection rule is one of the key factors for rational
design of AMPs. It would be of interest to investi-
gate if this selection rule can be applied to polymers
as a versatile mechanism. Weisshaar and coworkers
studied the mode of antimicrobial action by human
AMP LL-37 by real-time fluorescence spectroscopy.24
The peptide binds to the Escherichia coli surfaces and
translocates across the outer membrane (OM) after
reaching a threshold concentration of peptide on the
OM. Interestingly, the growth of E. coli was halted
by the peptide translocation across the OM before the
peptide was able to permeabilize the inner membrane
(IM). The peptide preferentially attacked septating
(dividing) cells and accumulated on the septum region,
which seems to be the weakest link in membrane
integrity. The peptide further diffused into the pepti-
doglycan layer and spread throughout the entire cell.
The peptide also permeabilized the IM, which is likely
to be the lethal step, although further investigation
is necessary. The real-time observation of single live
cells will be a strong tool to elucidate the mechanism
of antimicrobial polymers. In addition, it has been
postulated that the AMPs likely have multiple cel-
lular targets simultaneously such as cell membranes,
internal cellular components, and cell wall structures,
which may combine to a synergistic effect on their
activity.15,16,25,26 The multiplicity of targets allow us
classify AMPs as ‘dirty drugs’25,26 in contrast to con-
ventional antibiotics which have a specific molecular
target. Also, peptide binding generally exhibits lower
affinity when compared to high affinity, binding of
antibiotics to a specific target. The antibacterial mech-
anism of peptides utilizing these multiple low affinity
targets may be responsible for the low susceptibility of
peptides to the development of resistance mechanisms
in bacteria. These results indicate that the classical
model of killing by membrane permeabilization may
be incomplete. There appears to be a multifactorial
mechanism of action utilized by AMPs which would
also contribute to the lack of resistance seen against
these molecules. Which combinations of these killing
methods are utilized may also be dependent on the
specific peptide, bacterial target, and organismal envi-
ronment where the interaction occurs. Overall, this
creates the need for much more in-depth study of the
specific of mechanism of action of AMPs as well as
how these mechanisms can be recapitulated in small
molecules or in polymer frameworks.
Although the AMPs exhibit numerous beneficial
antimicrobial characteristics, there are also significant
hurdles to the large-scale implementation of AMPs
in a clinical setting.17,18,27,28 One of the primary
sets of issues with implementation of AMPs as
therapeutics relates to activity and availability
once delivered.18,29,30 The function and activity of
AMPs are often determined in controlled laboratory
environments in restricted, well-defined media sets.
This often leads to a decrease in functional activity
when the peptides are exposed to the complex serum
milieu, including numerous proteins and extracellular
structures that can nonspecifically sequester AMPs.
The delivery of AMPs is also a challenge in that
oral-availability is low due to the gastrointestinal
tract (GI) tract efficiently digesting peptide/protein
material. This fact necessitates additional carriers or
adjuvants to increase half-life and availability of orally
delivered peptides. Alternatively, intravenous delivery
is possible but limits the broad applicability for
antimicrobial applications, especially when compared
to the currently available small molecule antibiotics.
Another major issue is a high cost of manufacturing
peptide therapeutics on a large scale.17,18 Owing to
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their nature as antibacterial, large scale fermentations
and biologically based production are incompatible
with these molecules. The length and complexity of
most AMPs are also incompatible with solution-phase
chemical methodology, requiring time- and reagent-
intensive solid phase methods for production.
PEPTIDE-MIMETIC DESIGN
To address these obstacles of AMPs, synthetic poly-
mers have been designed as mimics of AMPs. In one
of the peptide studies, an all d-enantiomer magainin
homologs showed the same level of activity com-
pared to natural magainin.31 This indicated that the
antimicrobial action is not receptor-dependent, that
is, based on a specific protein–protein interaction.
In addition, many AMP structures share the same
physicochemical properties of a net positive charge
and contain several hydrophobic amino acid residues,
but yet no common consensus sequences or motifs
have been found.18 While a significant number of
known AMPs utilize the α-helical conformation to
create a facially amphiphilic, active structure, recent
evidence from the investigation of diastereomeric pep-
tides indicate that the stable helix structure may not
be necessary for activity.19,32 In this study, several
amino acids were substituted with d-enantiomers,
which disfavors helix formation. However, the pep-
tides were still found to adapt amphiphilic conforma-
tions with segregation of cationic and hydrophobic
residues, even without stable helix formation, when
bound to lipid membranes.19,32 These results suggest
that the cationic, amphiphilic properties, the three-
dimensional conformation of AMPs, or some balance
of these two factors are likely the key determinants for
antimicrobial activity rather than the exact sequence,
stereochemistry, and/or stable secondary structure.
Accordingly, the new design of antimicrobial polymers
has been focused to reflect the cationic amphiphilic
structures of AMPs on the synthetic polymer plat-
form rather than to mimic the secondary structural
conformations such as the α-helix.
In general, AMPs are relatively small, and
the cationic functionality is imparted by the pri-
mary ammonium groups of lysine. Accordingly,
polymer mimics of AMPs have been generated
to have low molecular weights (MWs) (a few
thousands) and primary ammonium side chains.11
Hydrophobic comonomers are also incorporated to
mimic the amphiphilic property of AMPs, producing
amphiphilic random copolymers. Several examples
of antimicrobial polymers are depicted in Figure 2.
Polymers with quaternary ammonium side chains
(polycations) have been widely utilized as polymeric
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FIGURE 2 | Several examples of antimicrobial peptide
(AMP)-mimicking polymers based on (a) methacrylate,37
(b) norbornene,38 (c) nylon,39 (d) vinyl ether,40 and (e) alternating
ring-opening metathesis polymerization (ROMP) copolymers41.
disinfectants and have high MWs in general.8,33–36
Considering the net positive charge of the amphiphilic
polymers, AMP-mimetic polymers can be also clas-
sified as polycations, but their low MW, primary
ammonium side chains, and hydrophobic components
provide new functionalities and characteristics includ-
ing polymer–lipid interactions and altered biological
activity. The roles of these factors are discussed below.
In the following sections, we discuss the antimi-
crobial activity and toxicity of polymers by focus-
ing the recent results from our laboratories.40,42–50
These polymers build on the fundamental amphiphilic,
cationic properties found in most AMPs and extend
them to platforms which are compatible for antimi-
crobial applications as well as being more scalable
for production. Many research groups are using dif-
ferent classes of polymers, different assay conditions,
and different strains of target bacteria, which result
in different measures of activity and data analysis. In
other words, antimicrobial effectiveness and toxicity
of polymers depend on assay conditions. Therefore,
direct comparisons of biological activities of polymers
including MIC, IC50, and cytotoxicity in literature
may be ambiguous, and can be qualitative at best.
This review discusses results from our work with
the peptide-mimetic design of antibacterial polymers
and their potential as new antimicrobials rather than
focusing on comparisons of efficacy with other classes
of polymers. The readers are advised to refer other
excellent review articles for more detailed discussions
on synthesis and mechanistic studies of other antimi-
crobial polymers.7–10,33,51
ANTIMICROBIAL ACTIVITY
Antimicrobial Assays
The activity of antimicrobial polymers against bacte-
ria is evaluated as inhibition effect on bacterial growth
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as well as bactericidal effect. The inhibition effect is
commonly measured as a minimum inhibitory concen-
tration (MIC) of polymers, which is the concentration
that completely inhibits bacterial growth. A micro-
dilution method using a microplate has been popular
because the assay protocol is relatively easy and suit-
able for testing large number of compounds on a small
scale. The standard and modified assay protocols are
available in literature.52,53 In general, known concen-
trations of bacteria are incubated with a range of
concentrations of polymers overnight, and bacterial
growth is determined by increase in the turbidity of
solution or optical density. It should be noted that
this assay determines no growth of bacteria, which
indicate the inhibition of bacterial growth by poly-
mers, but not necessarily due to killing of bacteria
by polymers. When the polymers inhibit the bacte-
rial growth without killing (bacteriostatic effect), the
bacteria are able grow again once the polymers are
removed by dilution or washing. The bacteriostatic
and bactericidal effects of polymers should be dis-
tinguished for proper data and mechanism analysis.
In addition, the micro-dilution assay is generally per-
formed by using a plastic multi-well microplate. It has
been reported that the activity of AMPs depends on the
properties of microplate plastics.54 AMPs showed low
activity in polystyrene (PS) microplate compared to a
polypropyrene (PP) microplate because amphiphilic
peptides can bind nonspecifically to the walls of
a PS plate, sequestering them from the bacterial
solution.53,54 Considering the amphiphilic property
of antimicrobial polymers, it is reasonable to assume
that the selection of microplates affects the results
of antimicrobial assay. On the other hand, bacteri-
cidal effect is evaluated as the number of residual
viable bacteria at given polymer concentrations or
the polymer concentrations necessary to kill certain
number of bacteria, typically >99.9% or 3-log reduc-
tion. The number of viable cells is usually reported by
colony forming units (cfu) determined through plating
assays.
Broad Spectrum of Activity
Antimicrobial polymers generally show broad-
spectrum activity against both Gram-positive and
negative bacteria. In contrast, conventional antibiotics
are usually more specific because their unique
cellular targets such as enzymes or DNA/RNA
replication inhibitors. The polymers show slightly
different activity against bacteria, but there seems
to be no general trend for preference in terms
of Gram-positive and negative strains. Methacrylate
copolymers displayed antimicrobial activity against
drug-resistant S. aureus (MRSA) with the same
level of activity with the drug-susceptible laboratory
strain47 (Table 1). The polymer is effective against A.
baumannii, which has developed significant resistance
against conventional antibiotic drugs. Recently, A.
baumannii infections are found among patients
treated at overseas military medical facilities.55 The
broad-spectrum activity of antimicrobial polymers can
be attributed to the membrane-disruption mechanism,
which is likely to be less sensitive to the specific
cell wall structures and lipid compositions in cellular
membranes.
Amphiphilic Polymer Structures and Activity
The antimicrobial activity of polymers in general
increases with increasing hydrophobic content in the
side chains. This is likely because of the increased
hydrophobicity of polymers enhancing insertion of
polymers into the hydrophobic region of cell mem-
branes. Our recent computational investigation on
methacrylate polymers indicated that the hydropho-
bic side chains of methacrylate random copolymers
are inserted into lipid bilayers (Figure 3(a) and (b)).47
It could be speculated that the polymer insertion to cell
membranes would be enhanced by the hydrophobicity
of side chains. In the same study, methacrylate ran-
dom copolymers are more deeply inserted into lipid
bilayers when the spacer arms in the cationic side
chain are elongated. This is because of the snorkeling
effect, in which the cationic ammonium groups are
bound to the anionic phosphate lipid head groups,
TABLE 1 Activity Spectrum of Representative Methacrylate
Copolymer (E429). (Reprinted with permission from Ref 47. Copyright
2012 American Chemical Society)
Bacteria or Human Cell MIC or HC50 (μg/mL)
E429 Melittin Magainin-2
Gram-positive
Staphylococcus aureus 63 6 >250
Staphylococcus aureus (CA-MRSA)1 31 n.d. n.d.
Enterococcus faecalis 31 16 >500
Bacillus subtilis 8 6 63
Gram-negative
Escherichia coli 21 12 125
Acinetobacter baumannii 10 n.d. n.d.
Pseudomonas aeruginosa 16 280 500
Salmonella enterica 16 140 500
Human RBC (HC50) 1300 2 >250
n.d., not determined.
1Community acquired methicillin-resistant S. aureus (MRSA) strain LAC
1236.
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FIGURE 3 | Simulated binding and insertion of methacrylate copolymers into lipid bilayers. (a) Model polymer structures with different cationic
spacer arm lengths, m = 2 (E2), 4 (E4), and 6 (E6). (b) Snapshots of polymers inserted into phosphatidylethanolamine/ palmitoyloleoylphosphatidyl
glycerol (POPE/POPG) lipid bilayers. (c) Conformation of E4 in the lipid bilayer. The polymer structures are presented by green (polymer backbone),
red (cationic side chains), and blue (hydrophobic ethyl side chains) colors. (Reprinted with permission from Ref 47. Copyright 2012 American
Chemical Society)
and the long arm or spacer enables the polymer chains
to separate from the membrane surface and sink into
the lipid bilayer (Figure 3(c)). The concept of snorkel-
ing effect has been developed originally in the peptide
science. Transmembrane peptides have been modified
to have extended spacer arms in ammonium (lysine
and guanidine) side chains. These long arms with
cationic groups can reach to the water–lipid interface,
which stabilizes the hydrophobic peptide helices in
the hydrophobic domains of lipid bilayers. Therefore,
the snorkeling effect can modulate the position and
orientation of transmembrane peptides.56–63 The sim-
ilar effect was found in our methacrylate copolymers
discussed above (Figure 3). Interestingly, the poly-
mer chain is stretched when they are bound to the
lipid bilayer, and the cationic groups and hydropho-
bic (ethyl) side chains of comonomers are segregated
relative to the polymer backbone. This amphiphilic
structure is similar to AMPs such as magainin, which
have also cationic and hydrophobic side chains seg-
regated into the different side of helix. Similarly,
Yethiraj and coworkers demonstrated that random
copolymer models of β-peptides bind to lipid bilayers
and form the segregated amphiphilic structures.64 The
amphiphilic structure of polymers and peptides when
bound to cell membranes may be the key determinant
rather than the identity and heterogeneity of chemical
structure and conformation.
To mimic the functionality of AMPs, antimi-
crobial polymers were prepared to have low MWs
and primary ammonium side chains, although this
design lacked any published experimental data to sup-
port the design. To that end, we investigated the
structure–activity relationship of methacrylate ran-
dom copolymers. To study the role of cationic side
chains, we hypothesized that the antimicrobial activ-
ity of copolymers would not depend on the chemical
structures of amine groups if the cationic net charge
of polymers were only essential in their underlying
antimicrobial mechanism. To test this hypothesis, we
investigated the effect of chemical structure of amine
groups (primary, tertiary and quaternary ammo-
nium) on the antimicrobial and hemolytic activities of
methacrylate copolymers (Figure 4(a)). The study indi-
cated that the methacrylate copolymers with primary
ammonium groups showed the highest activity while
the copolymers with quaternary ammonium groups
are not active. We speculate that the ammonium
groups form complexes with phosphate lipid heads
through a combination of electrostatic attraction
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and hydrogen bonding, enhancing the affinity of
copolymers for the lipid membrane and facilitating
membrane disruption.45 In addition, the methacrylate
copolymers are designed to have low MWs to mimic
AMPs. The MIC values of copolymers did not depend
on their MW significantly, but the copolymers showed
adverse hemolytic activity against human RBCs as the
MW was increased (Figure 5). The hemolytic activity
can be described by the partitioning of hydrophobic
side chains into lipid bilayers. Therefore, the high
MW copolymers have large number of hydrophobic
side chains, likely resulting in high hemolytic activity.
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FIGURE 5 | Killing kinetics. The polymers are PB27 (R = butyl,
27 mol. %) and PM63 (R = methyl, 63 mol. %). The copolymers are
tested at two times minimum inhibitory concentration (MIC) against
Staphylococcus aureus sub-cultured from the exponential (red closed
markers and solid lines) or stationary (blue open markers and dashed
lines) phase of S. aureus. The MICs of PB27 and PM63 are 16 μg/mL and
250 μg/mL, respectively. (Reprinted with permission from Ref 49.
Copyright 2011 MDPI)
These results indicate that tuning the balance of
amphiphilicity and MW of polymers is a key
strategy to generate nontoxic polymers with potent
antimicrobial activity. The hemolytic activity and
mechanism are discussed in detail below.
Cell Specificity
In general, antimicrobial polymers are good antimi-
crobial agents with a broad spectrum of activity
because their mechanism targets bacterial lipid mem-
branes, a cellular structure present in all bacterial
species. However, this ubiquitous target in turn makes
it difficult to target only specific strains by design.
However, several antibacterial polymers are known
to be selective against S. aureus over other strains,
although there is no report on polymers with selec-
tive activity to bacteria other than S. aureus. Cationic
polymers including polynorbornenes,38 oligolysins,65
and chitosan66 all showed selective activity against
S. aureus over E. coli. Although the chemical struc-
tures of these polymers are quite different from each
other, the cationic functionality appears to be in
common, which may be the key determinant in the
activity against S. aureus. Recently, our laborato-
ries also demonstrated that commercially available
unmodified polyethyleneimines (PEIs) with branched
structures (MW = 500–12,000) also are antimicrobial
with selective activity against S. aureus over E. coli.67
Interestingly, the natural AMP magainin did not show
significant activity against S. aureus while the peptide
is activity against E. coli under the same conditions.
Branched PEIs induced no membrane depolarization
of S. aureus even at high concentrations well above
MIC. It is possible that the antimicrobial action of
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PEIs is not to disturb the cell membranes, but act in
the cell wall.65,66 The cationic polymers may also be
trapped by the peptidoglycan layer of E. coli, inhibit-
ing polymer diffusion to the cytoplasmic membrane.68
Therefore, the selective activity of cationic polymers
may be linked to the structural difference in the bacte-
rial cell walls as well as differences in the antimicrobial
mechanism. Of note, since the tested strains are lim-
ited, it is not clear at this time that the activity of these
polymers is specific to Gram-positive strains general
or specifically for S. aureus. Although the mechanism
of cationic polymers for anti-S. aureus activity and
the selective activity is not clear yet, it would be of
interest for further investigation, which will provide
new insight into molecular design of next generation
antimicrobials.
Biocidal Kinetics
In order to assess the timeframe required for
antimicrobial polymers to kill bacteria, the number
of viable bacterial cells is determined as a function
of exposure time. In an assay, bacteria are incubated
with polymers, and an aliquot of this treated culture
is taken and diluted in buffer solution to remove
the effect of polymers. Then the diluted solution is
spread in an agar plate and incubated overnight to
allow formation of bacterial colonies. The number of
colonies on the agar plate is then counted. The assay
solution needs to be appropriately diluted such that
the final polymer concentration is much lower than
effective concentrations of polymers, otherwise, carry-
over of polymers may inhibit colony formation. But,
the bacteria concentration needs to be high enough
to give colonies in countable numbers for accuracy.
In principle, one bacterial cell forms one colony.
Therefore, the number of viable cells after incubation
with polymers can be calculated by taking the dilution
factors into account and reported as a colony-forming
unit (cfu). Typically these cfu values are converted into
the units cfu per a given volume (typically cfu/mL)
based on the dilution factors used and the volume of
assay solution that was applied to the plate.
In general, antimicrobial polymers display quick
bactericidal effect against bacteria: they kill more than
99.9% within an hour at the MIC, which is the
same level of effect with antibacterial peptides. In
our study on methacrylate copolymers, the effect of
growth phases of bacteria was also investigated.49 The
copolymers displayed no significant difference in the
killing rate against E. coli and S. aureus in the station-
ary and exponential growth phases (Figure 5). This
indicates that the mechanism of antimicrobial action
of the copolymers does not rely on the metabolic
physiological activity associated with bacterial growth
phases. Bacteria are less metabolically active when
they are in biofilms or exposed to antibiotics, which
is one of the bacterial defense mechanisms against
antibiotics which can then lead to the development
of antibiotic resistance. The copolymers we stud-
ied would likely be effective against bacteria in the
dormant state or in biofilms as well as being less
susceptible to resistance development through dor-
mancy. It should be noted that activity against bacteria
with decreased metabolic activity, as in biofilms, is
not the only challenge in efficacy against biofilms.
One of these challenges is that the cationic polymers
may become ‘trapped’ in the biofilm matrix com-
posed of anionic biopolymer exopolysaccharide (EPS),
which would limit the polymer diffusion and reduc-
ing their efficacy. However, compared to conventional
antibiotics, the potential activity of polymers against
dormant bacteria is poised to be a major advantage
for the development of these types of antimicro-
bial polymers effective against bacterial biofilms and
biofilm-associated infections.
TOXICITY TO HUMAN CELLS
Hemolysis
Lytic activity to red blood cells or hemolytic activ-
ity has been used as a measure of first assessment of
cytotoxicity of antimicrobial polymers. In a hemolysis
assay, the polymers are incubated with a suspension
of RBCs for a few hours. After centrifugation of assay
solution, red blood cells sediment to the bottom of ves-
sels or wells, and the amount of hemoglobin released in
the supernatant is determined spectroscopically. The
hemolytic activity of polymers is quantified by the per-
centage of released hemoglobin relative to 100% lysis
of all RBCs by, typically, a surfactant. As the poly-
mers are supposed to act on bacterial cell membranes,
damages to human cells are the first assessment for
cell selectivity. One of the reasons for popularity of
hemolysis is likely due to the easy assay procedure
compared to other cytotoxicity assays using prolifer-
able cells. It should be noted that there is no standard
protocol for hemolysis available which yields diffi-
cult comparisons between experimental systems and
molecular species in question. Hemolytic activity is
known to be very sensitive to the assay conditions as
isolated RBCs so care should be taken to minimize
experimental variability. One should employ extreme
caution when attempting to directly compare specific
values for hemolytic activity from the literature and
instead should primarily focus on behavioral trends.
In general, when methacrylate copolymers con-
tain a large amount of hydrophobic mass (either
by number of groups, size of groups, or both), the
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polymers behave as hydrophobic and hemolytic.50 The
polymers are expected to bind selectively to bacterial
cell surfaces over human cells because of electro-
static interaction. However, when the hydrophobicity
of polymers dominates the cellular binding of poly-
mers, the polymers start to bind nonspecifically to
both cell-types and cause hemolytic activity. As the
hydrophobic interaction is also the driving force
to enhance their antimicrobial activity, the balance
between hydrophobicity and cationic functionalities is
a key determinant for design of polymers with potent
activity and selective activity against bacteria over
human cells. Methacrylate copolymers with a range
of lengths (C1–C6) and contents of alkyl side chains
showed that the hemolytic activity can be described
by portioning of alkyl groups into the hydrophobic
domain of lipid bilayers (Figure 6).50 In addition, for
the copolymers with high contents of alkyl methacry-
lates, we observed polymer aggregates in water, which
decreases the number of polymer chains active or
accessible to cells, resulting in no enhancement of
activity by further increases in hydrophobicity.
How can we remove the hemolytic activity from
polymers without losing antimicrobial activity? This is
a million dollar question in the field. We have several
insights into the approach in polymer deign from our
laboratory and the literature. From the same study
on methacrylate copolymers,50 short alkyl side chains
seem to provide better selective activity compared to
counterparts with longer alkyl side chains. One of the
reasons may be because of small incremental changes
in hydrophobicity allowing fine-tuning of polymer
hydrophobicity for optimal balance between cationic
and hydrophobic groups. In addition, the polymers
need more methyl groups to get the same level of
activity as longer alkyl groups. This may indicate
that the distribution of hydrophobicity along the
polymer chain may be important. Indeed, cationic
amphiphilic vinyl ether block copolymers showed
little or no hemolytic activity compared to random
copolymers.40 Sen and coworkers demonstrated that
spatial separation of cationic charges and hydrophobic
groups in amphiphilic pyridium-methacrylate random
copolymers results in increased antimicrobial and
hemolytic activities, indicating a higher membrane-
disrupting ability.36 Although the chemical structures
of ammonium groups (primary ammonium vs pyrid-
ium) of these examples are different, the distribution of
hydrophobicity along the polymer chains and overall
amphiphilic sequences are one of the key determinants
to control the antimicrobial and hemolytic activi-
ties. The polymeric amphiphilic structure with tuned
hydrophobic distribution will be an interesting subject
for further research. In addition, the amphiphilicity of
polymers, polymer MW and MW distribution also
affect the hemolytic activity of polymers. In general,
low MW polymers are less hemolytic than high MW
counter parts.11,50,37 In the study on nylon polymers,
copolymers were purified by dialysis and the resultant
polymers are much less hemolytic.39 This indicates
that the high MW components in polydisperse poly-
mer samples are more responsible for hemolysis.
Although hemolysis has been widely used to
evaluate polymer toxicity, the hemolysis mechanism
has not been studied in detail. In this regard,
methacrylate copolymers have been reported to cause
all-or-none hemolysis, in which a fraction of RBCs
were lysed and released all hemoglobin into solution,
(a) (b)
1000
100
10
H
C 5
0 
(µM
)
0.1
0.01
0 10 20 30
Mole percentage of butyl groups (mol. %)
40 50 60 70
~8.700 (32–46)
~5.000 (19–31)
~1.600 (5–9)
0.1 1
Average number of side chains / polymer chain
10 100
1
1000
100
10MW (DP)
H
C 5
0 
/ µ
M
0.1
0.01
1
R:
Methyl
Ethyl
Butyl
Hexyl
Benzyl
O O
R
NH3
+
OO
n m
O O
NH3
+
OO
n m
FIGURE 6 | Hemolytic activity of methacrylate copolymers. (a) Molecular weight (MW) dependence of hemolytic activity. High MW copolymers
are more hemolytic. (b) Correlation between the number of hydrophobic groups in a polymer chain and HC50. (Reprinted with permission from Ref 50.
Copyright 2009 Wiley-VCH Verlag GmbH & Co. KGaA)
Volume 5, January/February 2013 © 2012 Wiley Per iodica ls, Inc. 57
Advanced Review wires.wiley.com/nanomed
120
100
80
60
D
is
ap
pe
ar
ed
 R
BC
s 
(%
)
40
20
0
0 20 40 60
Hemolysis (%)
80 100 120
All-or-none 
release
Graded 
release
0 25 50
Apparent hemolysis (%)
75
100
80
60
40
20
0
No 400
osmolyte
800 1200
PEG MW
1600
Melittin
PB27
Osmotic lysis
Hypotonic condition
H2O
H2O
H2O
H2O
H2O
H2O
+ Polymer
(a) (b) (c)
(d)
FIGURE 7 | All-or-none osmotic hemolysis induced by methacrylate polymer. The polymer PB27 contains 27 mol. % of butyl groups. (a) The
correlation between percentages of hemolysis (released hemoglobin) and disappeared cells. The good correlation suggests that the hemolysis caused
by the polymer is an all-or-none type event. (b) Schematic presentation of all-or-none and graded release of hemoglobin from RBCs. (c) Osmotic
protection by polyethylene glycols (PEGs). High molecular weight (MW) PEGs (> 1000) suppressed hemolysis by the polymer. The threshold MW of
PEG for hemolysis inhibition is 500–1000, corresponding to 1.6–2 nm in diameter. (d) Schematic representation of the osmotic lysis mechanism of
polymer action. (Reprinted with permission from Ref 48. Copyright 2011 American Chemical Society)
rather than all RBCs released a part of hemoglobin
(graded leakage) (Figure 7(a) and (b)).48 A hemoly-
sis assay using osmoprotectants such as polyethylene
glycols (PEGs) suggested that the copolymers form
nano-sized pores (1–2 nm in diameter) in RBC cell
membranes, causing osmotic lysis of RBCs due to
osmotic imbalance between the outer buffer solution
and the cytoplasm of RBCs (Figure 7(c) and (d)).
The bee venom toxin melittin also formed nano-pores
(∼2 nm), followed by osmolysis of RBCs. Although
the peptide and polymers have distinctive difference in
their chemical structures, they seem to share the same
underlying mechanism.
Cytotoxicity Assays
In addition to hemolysis, other standard cytotoxicity
assays have been used for assessment of toxicity of
antimicrobial polymers to mammalian cells, although
the number of reports is limited. One assay method
is to monitor a lease of lactate dehydrogenase (LDH)
from the cytoplasm, which reports damage to the
cell membrane.67 The released LDH is quantified
by spectroscopically monitoring product formation
catalyzed by the enzymatic reaction rather than the
direct detection of LDH, which contrasts to the
hemolysis assay. An MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay has been
also used for cell viability.69 This method detects the
metabolic activity of cells using a substrate which
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produces distinctive color change when reduced by
active components of normal cellular metabolism.
Recently, a water-soluble version of substrate, XTT
(sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino)-carbonyl]-2H-tetrazolium), has been
used for the same assay to facilitate the procedure.67
Combining these assay methods, we are able to char-
acterize the cytotoxicity of polymers as well as giving
insights into the mechanism of cytotoxicity. These
assays have been utilized for cationic polymers.69
In our recent report, antimicrobial branched PEIs
with low MWs (MW = 500 and 1100) showed no
release of LDH from human epithelial HEp-2 cells,
but the cell viability was reduced significantly after
24-h incubation.67 This indicates that PEIs do not
damage the cell membranes, but may cause potential
long-term toxicity to host cells. In the literature, the
cytotoxicity of antimicrobial polymers has not been
fully evaluated. It would be important to investigate
the interaction between antimicrobial polymers and
host cells toward clinical applications.
ANTIMICROBIAL RESISTANCE
IN BACTERIA
Low susceptibility to the existing or emerging resis-
tance mechanisms is one of the hallmarks of AMPs.
Although the number of reports is limited, some
antimicrobial peptidomimetics and polymers appear
to be effective against strains already resistant to
conventional antibiotics and do not contribute to
the development of new antimicrobial resistance.49,70
We have investigated the occurrence of resistance in
E. coli using methacrylate copolymers (Figure 8).49
Methacrylate copolymers at half the MIC were incu-
bated with E. coli, and the solution was cultured
overnight. Then the copolymers were tested against
the bacterial cells, and MIC was determined. The bac-
teria were cultured again at half of the new MIC,
and MIC was determined after overnight incubation.
In this assay, if the bacteria develop resistance, the
MIC increases and thus the amount of antibiotics
increase at the subsequent culture. Therefore, this
condition is likely to stimulate and accelerate the
resistance development in bacteria. After 21 passages
of this process, the MIC values of conventional antibi-
otics Ciprofloxacin and Norfloxacin increased 200-
and 500-fold higher, indicating significant resistance
development. On the other hand, the MIC values of
methacrylate copolymers did not increase, indicating
no resistance development under this condition. The
bacteria incubated with the copolymers were suscep-
tible to the antibiotics Norfloxacin and Ciprofloxacin,
and the copolymers were active against bacteria
resistant to these antibiotics. This demonstrates that
the copolymers do not contribute to cross-resistance
development in bacteria.
FACTORS TO INFLUENCE ACTIVITY
It has been reported that environmental factors inhibit
the activity of AMPs and polymers.17 For the imple-
mentation of antimicrobial polymers in biomedical
applications, it is important to evaluate the polymer
activity in the physiological conditions and to under-
stand the factors that affect the activity. These factors
that affect efficacy can be widely variable, but a good
starting point are the variables that relate to the mech-
anism of action of the polymers in question. In the
case of the antimicrobial polymers described here, the
polymer selectivity relies on electrostatic interactions
while the membrane disruptive activity relies primar-
ily on hydrophobic interactions. As such, the role of
pH, ionic strength, and serum components that have
some hydrophobic character are likely modulators of
in vivo efficacy.
Solution pH
The polymers and peptides described have primary
amine groups, which exhibits a pH dependence on
ionization behavior. It has been demonstrated that
solution pH changes polymer’s antimicrobial activity
(Figure 9). In the study on methacrylate copolymers,
copolymers were tested for their activity againstE. coli
between pH 6 and 8.44 The copolymers showed higher
activity at higher pH. These data suggest that the
copolymers are likely more hydrophobic due to the
increased population of nonprotonated amine groups
at higher pH, which are less hydrophilic (and hence
more hydrophobic) than the charged versions of these
moieties. It should be noted that uncharged primary
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amines are not truly hydrophobic unlike hydrophobic
side chain groups (methyl) in comonomers, which are
expected to actively interact with the hydrophobic
domains of lipid membranes. The deprotonation of
ammonium groups reduces the solvation (hydration)
of polymers, resulting in a shift of amphiphilic balance
of polymers to a more hydrophobic character and
thus increased antimicrobial and hemolytic activities
as the solution pH increases. This supports the notion
that the hydrophobicity of copolymers increased,
which dominate the electrostatic attraction between
the copolymers and bacterial cell surfaces, causing
nonselective binding to both cells. The number of
cationic protonated ammonium groups decreases as
pH increases, and the affinity of copolymers to
bacterial cell surfaces could be reduced. However, it is
evident that the overall hydrophobicity of copolymers
is more effective to increase the antimicrobial activity.
It has been known that the ammonium groups
are cationic sources for selective binding to anionic
bacterial cell wall, resulting in selective toxicity
to bacteria over human cells. What if the anime
groups are always charged? To this end, methacrylate
copolymers with primary, tertiary, and quaternary
ammonium groups in the side chains were prepared
and their activity was measured.44 The copolymers
with primary ammonium groups showed highest
activity against E. coli. The activity was further tested
in different pH conditions. According to separated
potentiometirc titrations, most of amine groups are
protonated at pH 6, suggesting all polymers have the
same number of cationic groups in a polymer chain.
It is interesting that the copolymers with primary
ammonium groups showed the highest activity against
E. coli again. These results suggest that the amine
groups are not only cationic sources, but they are
acting in the lipid–polymer interactions. The further
investigation by examining partition of copolymers
between water and octanol suggested that the primary
ammonium groups are likely to form complex with
phosphate lipid heads through hydrogen bonding and
electrostatic interaction (Figure 4).45 This complex
formation might increase the affinity of copolymers
with primary ammonium groups for bacterial cells as
well as possibly enhances the antimicrobial mecha-
nism of membrane disruption or pore formation.
Ionic Strength and Divalent Ions
As polymer binding to bacteria relies on electrostatic
interaction, high salt concentration (ionic strength)
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curtains the attractive interactions between polymers
and bacteria, resulting in low affinity and low activity.
The methacrylate copolymers showed twofold to
fourfold increase in MIC against E. coli in Mueller
Hinton (MH) broth with additional 150 mM NaCl
(Figure 10).49 Divalent cations Mg and Ca also reduce
the activity of polymers.49 The activity of methacrylate
copolymers was twofold reduced in the presence of
these cations (1 mM). These cations are structural
ions, which stabilize the lipopolysaccharide (LPS)
structures on the cell surfaces, preventing membrane
disruption by the polymers. The high concentration
of these cations may also reduce the replacement of
cations in the LPS by the cationic groups of polymers,
which prevent disintegration of membrane structure.
Serum Proteins
When AMPs are tested in the presence of serum,
the peptides’ activity is significantly reduced.17,71,72
This has been attributed to enzymatic degradation of
peptide chains (proteolysis), high ionic strength, and
nonspecific binding to serum proteins such as bovine
serum albumin (BSA). It seems that activity of poly-
mers in serum or physiological fluids have not been
evaluated to the same degree, and of those studies
available, many focus on the interaction of serum
components with surface-attached polymers and not
soluble structures as described herein. Similar to the
case of AMPs, the increased ionic strength of the
serum environment may screen the electrostatic attrac-
tive interactions between the cationic groups on the
polymers and the intended bacterial surface targets.
Alternatively, the nonpolar moieties present in antimi-
crobial polymers may drive nonspecific hydrophobic
clustering with larger serum proteins. In the case of
antimicrobial polymers, a majority of compatibility
testing has relied on simple protein adsorption assays
in which a standard serum protein, such as BSA,
is used to test for nonspecific interactions with
the polymers.73,74 The complex serum environment
engenders the need for future investigation of these
complexities that may modify the efficacy and selec-
tivity of antimicrobial polymers.
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NEW DESIGN STRATEGIES FOR
ANTIMICROBIAL POLYMERS
Amphiphilic Polymer Structures
Random copolymers have been traditionally used as
a platform to generate antimicrobial polymers. The
random copolymers may form conformations which
display segregated or facially amphiphilic structures
by separating cationic side chains and hydrophobic
moieties in the membrane interface.47,39 This mimics
the amphiphilic structures of α-helical AMPs such
as magainin and LL-37. On the other hand,
antimicrobial and hemolytic activities of amphiphilic
block copolymers have been investigated recently.40,75
We have recently demonstrated that amphiphilic block
copolymers are also good antimicrobial candidates
with selective activity against bacteria over human
cells (Figure 11).40 Vinyl ether di-block copolymers
with cationic and hydrophobic segments showed
biocidal effect against E. coli, but cause little or no
hemolysis. However, the random copolymers with
the same ratio of cationic and hydrophobic moieties
are highly hemolytic, although the polymers showed
the same level of biocidal activity against E. coli
as compared to the block copolymer counterparts.
The block copolymers appear to form vesicles at
high concentrations. However, the block copolymers
showed significant antimicrobial activity even below
the critical micelle concentration of polymers,
indicating the vesicle formation is not necessarily
required for selective antimicrobial activity against
E. coli over human RBCs. This suggests that the
conformation of single polymer chains is responsible
for the activity. In general, hydrophobic segments of
amphiphilic copolymers aggregate in water and form
hydrophobic domains which can be shielded from the
aqueous milieu by the solvated hydrophilic segments,
resulting in intramolecular or intermolecular micelle
formation.76 We speculated that the cationic segment
of block copolymers wrapped around the hydrophobic
segment, creating a low-energy structure in the
aqueous environment, curtaining the hydrophobic
domains and preventing nonspecific binding to human
cells (see Ref 40 for the schematic presentation).
This is a prevailing theory in the field regarding the
structural conformations of hydrophobic/hydrophilic
block copolymers.76 On the other hand, the random
copolymers would likely adopt a random-coil
conformation because the hydrophobic groups are
distributed along the polymer chains.77 In these cases,
many hydrophobic groups are likely located outside
of any hydrophobic core and relatively exposed
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to the solution, which can easily facilitate interac-
tion with RBC cell membranes and cause hemolysis.
This study provided a new insight into the impor-
tant role which amphiphilic polymer structures play
in their antimicrobial mechanism. In addition, it
has been demonstrated that nanoparticles formed by
amphiphilic block copolymers are effective against
a broad spectrum of fungi and bacteria including
a drug-resistant strain.78,79 The molecular design
for the next generation of antimicrobial polymers
will be extended to include macromolecular struc-
tures and architectures that build on the increasing
mechanistic understanding of both polymeric and pep-
tide antimicrobials. These should take advantage of
the known molecular components that contribute to
specificity and efficacy, while additionally incorporat-
ing beneficial properties to aid in bioavailability and
delivery.
Biodegradable Antimicrobial Copolymers
Antimicrobial polymers with synthetic biodegradable
backbones including, for example, esters and carbon-
ate groups have been reported.78,80–82 Our research
group has prepared polyester-based amphiphilic
copolymers with cationic side chains by simulta-
neous chain- and step-growth radical polymerization
(Figure 12).43 The random copolymers contain pri-
mary ammonium groups in the side chains and ester
linkages in the polymer backbone. The copolymers
displayed antibacterial activity against E. coli, but
degraded into oligomers at neutral pH, and the
activity of copolymer decreased. The detailed inves-
tigation using control copolymers with acidic side
chains instead of amine groups, we speculate that
the primary amine groups in the side chains react
with the ester groups of the polymer backbone, and
the following amidation cleaves the polymer chains.
This self-degradation mechanism will be useful for
quick disintegration of polymer chains into inactive
oligomers, avoiding potential toxicity after long-term
exposure.
CONCLUSION
Antimicrobial polymers are potential candidates
for antibiotics, which would be effective against
drug-resistant bacteria and would not contribute to
resistance development. This is likely because the poly-
mers act in the cell membranes or cell walls as mimics
of AMPs, although the molecular mechanism is not
fully understood yet at this point. There are distinc-
tive differences in their structures and conformations
between AMPs and antimicrobial polymers. AMPs
have homogeneous structures (defined sequence and
molecular length) and are programmed to form a helix
with regulated amphiphilicity (Figure 1). On the other
hand, synthetic polymers are heterogeneous in terms
of chemical structures (random sequences, MW dis-
tribution, and tacticity) and structural conformations
(random coil). Despite these differences, antimicrobial
polymers are effective against bacteria and selective
to bacteria over human cells to the same degree as
AMPs. This may indicate that the physicochemical
properties of polymers and peptides are important
for antimicrobial action rather than the structures
while it remains still a question whether synthetic
copolymers have the same molecular mechanism(s) of
AMPs.
We envision that these polymers are most
immediately useful for potential applications as top-
ical antimicrobial agents including targets such as
periodontal disease and dermatological applications.
However, before this point, there remain many lim-
itations and hurdles to overcome before moving to
clinical applications. For example, there has been
little investigation into potential side effects caused
by the polymeric antimicrobials. While the selectivity
for bacterial cells over mammalian cells is a positive
indicator of compatibility, the long-term application
of these molecules and their possible interactions with
natural flora and/or interaction with complex phys-
iological systems must be investigated. This is likely
to be more involved than the peptidic counterparts as
the potential for wildly different polymer backbones,
compositions, and sizes will increase the need for
individualized studies.
At this moment, there are only a few polymers
identified as effective agents, and the translational
studies of these polymers are still limited. However,
the scientific reports on antimicrobial polymers have
increased significantly over the last two decades, and
new advanced chemical methodologies have been
utilized to improve the polymer performance. Many
different kinds of polymer structures have already
been developed much like AMPs which also have
large diversity in their chemical structures. This sug-
gests that the AMP-mimetic design of polymers will
continue to be versatile and applicable to numer-
ous polymer types, which will in turn facilitate the
implementation of antimicrobial polymers as a new
generation of antibiotics.
Volume 5, January/February 2013 © 2012 Wiley Per iodica ls, Inc. 63
Advanced Review wires.wiley.com/nanomed
REFERENCES
1. Fernandes P. Antibacterial discovery and development
- the failure of success? Nat Biotechnol 2006, 24:
1497–1503.
2. Fischbach MA, Walsh CT. Antibiotics for emerging
pathogens. Science 2009, 325:1089–1093.
3. Levy SB. The Antibiotic Paradox. How Miracle Drugs
Are Destroying the Miracle. New York: Plenum Press;
1992.
4. Levy SB. Antibiotic resistance: an ecological imbalance.
In: Chadwick DJ, Goode J, eds. Antibiotic Resistance:
Origins, Evolution, Selection and Spread. 207 ed.
Chichester: Wiley; 1997,1–14.
5. Levy SB, Marshall B. Antibacterial resistance world-
wide: causes, challenges and responses. Nat Med 2004,
10:S122–S129.
6. Nathan C. Antibiotics at the crossroads. Nature 2004,
431:899–902.
7. Gabriel GJ, Som A, Madkour AE, Eren T, Tew GN.
Infectious disease: connecting innate immunity to bio-
cidal polymers. Mater Sci Eng R 2007, 57:28–64.
8. Kenawy ER, Worley SD, Broughton R. The chem-
istry and applications of antimicrobial polymers:
a state-of-the-art review. Biomacromolecules 2007,
8:1359–1384.
9. Li P, Li X, Saravanan R, Li CM, Leong SSJ. Antimi-
crobial macromolecules: synthesis methods and future
applications. RSC Adv 2012, 2:4031–4044.
10. Timofeeva L, Kleshcheva N. Antimicrobial polymers:
mechanism of action, factors of activity, and applica-
tions. Appl Microbiol Biotechnol 2011, 89:475–492.
11. Palermo EF, Kuroda K. Structural determinants of
antimicrobial activity in polymers which mimic host
defense peptides. Appl Microbiol Biotechnol 2010,
87:1605–1615.
12. Epand RF, Mowery BP, Lee SE, Stahl SS, Lehrer RI,
Gellman SH, Epand RM. Dual mechanism of bacte-
rial lethality for a cationic sequence-random copolymer
that mimics host-defense antimicrobial peptides. J Mol
Biol 2008, 379:38–50.
13. Gabriel GJ, Pool JG, Som A, Dabkowski JM,
Coughlin EB, Muthukurnar M, Tew GN. Interac-
tions between antimicrobial polynorbornenes and
phospholipid vesicles monitored by light scattering and
microcalorimetry. Langmuir 2008, 24:12489–12495.
14. Rawlinson L-AB, Ryan SM, Mantovani G, Syrett JA,
Haddleton DM, Brayden DJ. Antibacterial effects
of poly(2-(dimethylamino ethyl)methacrylate) against
selected Gram-positive and Gram-negative bacteria.
Biomacromolecules 2010, 11:443–453.
15. Brogden KA. Antimicrobial peptides: pore formers or
metabolic inhibitors in bacteria? Nat Rev Microbiol
2005, 3:238–250.
16. Zasloff M. Antimicrobial peptides of multicellular
organisms. Nature 2002, 415:389–395.
17. Marr AK, Gooderham WJ, Hancock REW. Antibacte-
rial peptides for therapeutic use: obstacles and realistic
outlook. Curr Opin Pharmacol 2006, 6:468–472.
18. Hancock REW, Sahl HG. Antimicrobial and host-
defense peptides as new anti-infective therapeutic strate-
gies. Nat Biotechnol 2006, 24:1551–1557.
19. Shai Y. Mode of action of membrane active antimicro-
bial peptides. Biopolymers 2002, 66:236–248.
20. Rodriguez de Castro F, Naranjo OR, Marco JA,
Violan JS. New antimicrobial molecules and new antibi-
otic strategies. Semin Respir Crit Care Med 2009,
30:161–171.
21. Matsuzaki K. Why and how are peptide-lipid interac-
tions utilized for self-defense? Magainins and tachy-
plesins as archetypes. Biochim Biophys Acta Biomem-
branes 1999, 1462:1–10.
22. Tossi A, Sandri L, Giangaspero A. Amphipathic, α-
helical antimicrobial peptides. Biopolymers 2000,
55:4–30.
23. Schmidt NW, Mishra A, Lai GH, Davis M, Sanders LK,
Dat T, Garcia A, Tai KP, McCray PB, Jr. Ouellette AJ,
et al. Criterion for amino acid composition of defensins
and antimicrobial peptides based on geometry of
membrane destabilization. J Am Chem Soc 2011,
133:6720–6727.
24. Sochacki KA, Barns KJ, Bucki R, Weisshaar JC. Real-
time attack on single Escherichia coli cells by the human
antimicrobial peptide LL-37. Proc Natl Acad Sci U S A
2011, 108:E77–E81.
25. Peschel A, Sahl H-G. The co-evolution of host cationic
antimicrobial peptides and microbial resistance. Nat
Rev Microbiol 2006, 4:529–536.
26. Franco OL. Peptide promiscuity: an evolutionary con-
cept for plant defense. FEBS Lett 2011, 585:995–1000.
27. Hancock REW, Lehrer R. Cationic peptides: a new
source of antibiotics. Trends Biotechnol 1998,
16:82–88.
28. Giuliani A, Pirri G, Nicoletto S. Antimicrobial peptides:
an overview of a promising class of therapeutics. Cent
Eur J Biol 2007, 2:33.
29. Papo N, Shai Y. Host defense peptides as new
weapons in cancer treatment. Cell Mol Life Sci 2005,
62:784–790.
30. Riedl S, Zweytick D, Lohner K. Membrane-active host
defense peptides - challenges and perspectives for the
development of novel anticancer drugs. Chem Phys
Lipids 2011, 164:766–781.
31. Wade D, Boman A, Wahlin B, Drain CM, Andreu D,
Boman HG, Merrifield RB. All-d amino acid-containing
channel-forming antibiotic peptides. Proc Natl Acad Sci
U S A 1990, 87:4761–4765.
32. Oren Z, Ramesh J, Avrahami D, Suryaprakash N,
Shai Y, Jelinek R. Structures and mode of mem-
brane interaction of a short α helical lytic peptide
64 © 2012 Wiley Per iodica ls, Inc. Volume 5, January/February 2013
WIREs Nanomedicine and Nanobiotechnology Antimicrobial polymers
and its diastereomer determined by NMR, FTIR,
and fluorescence spectroscopy. Eur J Biochem 2002,
269:3869–3880.
33. Tashiro T. Antibacterial and bacterium adsorb-
ing macromolecules. Macromol Mater Eng 2001,
286:63–87.
34. Chakrabarty S, King A, Kurt P, Zhang W, Ohman DE,
Wood LF, Lovelace C, Rao R, Wynne KJ. Highly
effective, water-soluble, hemocompatible 1,3-
propylene oxide-based antimicrobials: poly[(3,3-
quaternary/PEG)-copolyoxetanes]. Biomacromolecules
2011, 12:757–769.
35. Stratton TR, Rickus JL, Youngblood JP. In vitro bio-
compatibility studies of antibacterial quaternary poly-
mers. Biomacromolecules 2009, 10:2550–2555.
36. Sambhy V, Peterson BR, Sen A. Antibacterial and
hemolytic activities of pyridinium polymers as a func-
tion of the spatial relationship between the positive
charge and the pendant alkyl tail. Angew Chem Int Ed
2008, 47:1250–1254.
37. Kuroda K, DeGrado WF. Amphiphilic polymethacry-
late derivatives as antimicrobial agents. J Am Chem Soc
2005, 127:4128–4129.
38. Lienkamp K, Madkour AE, Musante A, Nelson CF,
Nusslein K, Tew GN. Antimicrobial polymers prepared
by ROMP with unprecedented selectivity: a molecu-
lar construction kit approach. J Am Chem Soc 2008,
130:9836–9843.
39. Mowery BP, Lee SE, Kissounko DA, Epand RF, Epand
RM, Weisblum B, Stahl SS, Gellman SH. Mimicry of
antimicrobial host-defense peptides by random copoly-
mers. J Am Chem Soc 2007, 129:15474–15476.
40. Oda Y, Kanaoka S, Sato T, Aoshima S, Kuroda K.
Block versus random amphiphilic copolymers
as antibacterial agents. Biomacromolecules 2011,
12:3581–3591.
41. Song A, Walker SG, Parker KA, Sampson NS. Antibac-
terial studies of cationic polymers with alternating,
random, and uniform backbones.ACSChemBiol 2011,
6:590–599.
42. Avery CW, Palermo EF, McLaughin A, Kuroda K,
Chen Z. Investigations of the interactions between syn-
thetic antimicrobial polymers and substrate-supported
lipid bilayers using sum frequency generation vibra-
tional spectroscopy. Anal Chem 2011, 83:1342–1349.
43. Mizutani M, Palermo EF, Thoma LM, Satoh K, Kami-
gaito M, Kuroda K. Design and synthesis of self-
degradable antibacterial polymers by simultaneous
chain- and step-growth radical copolymerization.
Biomacromolecules 2012, 13:1554–1563.
44. Palermo EF, Kuroda K. Chemical structure of cationic
groups in amphiphilic polymethacrylates modulates
the antimicrobial and hemolytic activities. Biomacro-
molecules 2009, 10:1416–1428.
45. Palermo EF, Lee DK, Ramamoorthy A, Kuroda K. Role
of cationic group structure in membrane binding and
disruption by amphiphilic copolymers. J Phys Chem B
2011, 115:366–375.
46. Palermo EF, Sovadinova I, Kuroda K. Structural deter-
minants of antimicrobial activity and biocompatibil-
ity in membrane-disrupting methacrylamide random
copolymers. Biomacromolecules 2009, 10:3098–3107.
47. Palermo EF, Vemparala S, Kuroda K. Cationic spacer
arm design strategy for control of antimicrobial activity
and conformation of amphiphilic methacrylate random
copolymers. Biomacromolecules 2012, 13:1632–1641.
48. Sovadinova I, Palermo EF, Huang R, Thoma LM,
Kuroda K. Mechanism of polymer-induced hemolysis:
nanosized pore formation and osmotic lysis. Biomacro-
molecules 2011, 12:260–268.
49. Sovadinova IP, Urban EF, Mpiga M, Caputo P,
Kuroda GA. K Activity and mechanism of antimicrobial
peptide-mimetic amphiphilic polymethacrylate deriva-
tives. Polymers 2011, 3:1512–1532.
50. Kuroda K, Caputo GA, DeGrado WF. The role of
hydrophobicity in the antimicrobial and hemolytic
activities of polymethacrylate derivatives. Chem Eur
J 2009, 15:1123–1133.
51. Munoz-Bonilla A, Fernandez-Garcia M. Polymeric
materials with antimicrobial activity. Prog Polym Sci
2012, 37:281–339.
52. NCCLS. Approved standards M7-A3. Methods for
Dilution Antimicrobial Susceptibility Tests for Bacte-
ria That Grow Aerobically. Philadelphia, PA: NCCLS;
2003.
53. Wiegand I, Hilpert K, Hancock REW. Agar and broth
dilution methods to determine the minimal inhibitory
concentration (MIC) of antimicrobial substances. Nat
Protoc 2008, 3:163–175.
54. Giacometti A, Cirioni O, Barchiesi F, Del Prete MS,
Fortuna M, Caselli F, Scalise G. In vitro susceptibility
tests for cationic peptides: comparison of broth microdi-
lution methods for bacteria that grow aerobically.
Antimicrob Agents Chemother 2000, 44:1694–1696.
55. Centers for Disease Control and Prevention. Acine-
tobacter baumannii infections among patients at
military medical facilities treating injured U.S. ser-
vice members, 2002–2004. Morbid Mortal Week
Rep 2004, Available at: http://www.cdc.gov/mmwr/
preview/mmwrhtml/mm5345a1.htm.
56. Caputo GA, London E. Cumulative effects of amino
acid substitutions and hydrophobic mismatch upon
the transmembrane stability and conformation of
hydrophobic α-helices. Biochem 2003, 42:3275–3285.
57. Jaud S, Fernandez-Vidal M, Nilsson I, Meindi-Beinker
NM, Hubner NC, Tobias DJ, von Heijne G, White SH.
Insertion of short transmembrane helices by the
Sec61 translocon. Proc Natl Acad Sci U S A 2009,
106:11588–11593.
58. Krishnakumar SS, London E. The control of trans-
membrane helix transverse position in membranes by
hydrophilic residues. J Mol Biol 2007, 374:1251–1269.
Volume 5, January/February 2013 © 2012 Wiley Per iodica ls, Inc. 65
Advanced Review wires.wiley.com/nanomed
59. Mishra VK, Palgunachari MN, Segrest JP, Ananthara-
maiah GM. Interactions of synthetic peptide analogs
of the class a amphipathic helix with lipids - evi-
dence for the snorkel hypothesis. J Biol Chem 1994,
269:7185–7191.
60. Monne M, Nilsson I, Johansson M, Elmhed N, von
Heijne G. Positively and negatively charged residues
have different effects on the position in the membrane
of a model transmembrane helix. J Mol Biol 1998,
284:1177–1183.
61. Schow EV, Freites JA, Cheng P, Bernsel A, von Hei-
jne G, White SH, Tobias DJ. Arginine in membranes:
the connection between molecular dynamics simula-
tions and translocon-mediated insertion experiments.
J Membr Biol 2011, 239:35–48.
62. Strandberg E, Killian JA. Snorkeling of lysine side
chains in transmembrane helices: how easy can it get?
FEBS Lett 2003, 544:69–73.
63. Strandberg E, Morein S, Rijkers DTS, Liskamp RMJ,
van der Wel PCA, Killian JA. Lipid dependence of mem-
brane anchoring properties and snorkeling behavior of
aromatic and charged residues in transmembrane pep-
tides. Biochem 2002, 41:7190–7198.
64. Mondal J, Zhu X, Cui QA, Yethiraj A. Sequence-
dependent interaction of β-peptides with membranes.
J Phys Chem B 2010, 114:13585–13592.
65. Epand RF, Sarig H, Mor A, Epand RM. Cell-wall
interactions and the selective bacteriostatic activ-
ity of a miniature oligo-acyl-lysyl. Biophys J 2009,
97:2250–2257.
66. Raafat D, von Bargen K, Haas A, Sahl H-G. Insights
into the mode of action of chitosan as an antibac-
terial compound. Appl Environ Microbiol 2008, 74:
3764–3773.
67. Gibney K, Sovadinova I, Lopez AI, Urban M, Ridgway
Z, Caputo GA, Kuroda K. Poly(ethylene imine)s as
antimicrobial agents with selective activity. Macromol
Biosci 2012, 12:1279–1289.
68. Lienkamp K, Kumar K-N, Som A, Nuesslein K,
Tew GN. ‘‘Doubly selective’’ antimicrobial polymers:
how do they differentiate between bacteria? Chem Euro
J 2009, 15:11710–11714.
69. Fischer D, Li YX, Ahlemeyer B, Krieglstein J, Kissel T.
In vitro cytotoxicity testing of polycations: influence
of polymer structure on cell viability and hemolysis.
Biomaterials 2003, 24:1121–1131.
70. Tew GN, Clements D, Tang HZ, Arnt L, Scott RW.
Antimicrobial activity of an abiotic host defense pep-
tide mimic.Biochim Biophys Acta Biomembranes 2006,
1758:1387–1392.
71. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP,
Zasloff M, Wilson JM. Human β-defensin-1 is a salt-
sensitive antibiotic in lung that is inactivated in cystic
fibrosis. Cell 1997, 88:553–560.
72. Maisetta G, Di Luca M, Esin S, Florio W, Brancati-
sano FL, Bottai D, Campa M, Batoni G. Evaluation of
the inhibitory effects of human serum components on
bactericidal activity of human β defensin 3. Peptides
2008, 29:1–6.
73. Nie N, Tu Q, Wang J-C, Chao F, Liu R, Zhang Y,
Liu W, Wang J. Synthesis of copolymers using den-
dronized polyethylene glycol and assay of their blood
compatibility and antibacterial adhesion activity. Col-
loids Surfaces B 2012, 97:226–235.
74. Yang WJ, Cai T, Neoh K-G, Kang E-T, Dickinson GH,
Teo SL-M, Rittschof D. Biomimetic anchors for
antifouling and antibacterial polymer brushes on stain-
less steel. Langmuir 2011, 27:7065–7076.
75. Wang YQ, Xu JJ, Zhang YH, Yan HS, Liu KL. Antimi-
crobial and hemolytic activities of copolymers with
cationic and hydrophobic groups: a comparison of
block and random copolymers. Macromol Biosci 2011,
11:1499–1504.
76. Chu B. Structure and dynamics of block-copolymer col-
loids. Langmuir 1995, 11:414–421.
77. Tominaga Y, Mizuse M, Hashidzume A, Morishima Y,
Sato T. Flower micelle of amphiphilic random copoly-
mers in aqueous media. J Phys Chem B 2010,
114:11403–11408.
78. Nederberg F, Zhang Y, Tan JPK, Xu K, Wang H,
Yang C, Gao S, Guo XD, Fukushima K, Li L, et al.
Biodegradable nanostructures with selective lysis of
microbial membranes. Nat Chem 2011, 3:409–414.
79. Liu L, Xu K, Wang H, Tan JPK, Fan W, Venkatra-
man SS, Li L, Yang Y-Y. Self-assembled cationic pep-
tide nanoparticles as an efficient antimicrobial agent.
Nat Nanotechnol 2009, 4:457–463.
80. Rosenberg LE, Carbone AL, Romling U, Uhrich KE,
Chikindas ML. Salicylic acid-based poly(anhydride
esters) for control of biofilm formation in Salmonella
enterica serovar typhimurium. Lett Appl Microbiol
2008, 46:593–599.
81. Woo GLY, Mittelman MW, Santerre JP. Synthesis and
characterization of a novel biodegradable antimicrobial
polymer. Biomaterials 2000, 21:1235–1246.
82. Zawaneh PN, Singh SP, Padera RF, Henderson PW,
Spector JA, Putnam D. Design of an injectable synthetic
and biodegradable surgical biomaterial. Proc Natl Acad
Sci U S A 2010, 107:11014–11019.
66 © 2012 Wiley Per iodica ls, Inc. Volume 5, January/February 2013
